BPC June 03 update

Adamis ADMP shares spike on NIH early COVID-19 anti-viral research for Tempol +61%

Price and Volume Movers

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) shares closed up 61% to $1.13, spiking during mid-afternoon trading following a news release by the National Institutes of Health (NIH) that researchers have identified Tempol as a potential new antiviral drug for COVID-19 following research on cell cultures. The research is in its very early stage, with the team planning on conducting additional animal studies and will seek opportunities to evaluate Tenpol in clinical trials of COVID-19.

Nanobiotix (NASDAQ: NBTX) announced the upcoming presentation of updated data from its Phase 1 trial of NBTXR3 for the annual American Society for Clinical Oncology (ASCO) meeting. As of the data cut-off, 16 patients received NBTXR3 plus radiotherapy and 13 were evaluable for response. Tumor regression was observed in 76.9% (10/13) of evaluable patients, regardless of prior anti-PD-1 exposure. Abstracts from all companies presenting at ASCO will be released tomorrow.

BriaCell Therapeutics Corp. (NASDAQ:BCTX) announced a private placement with investors, which will result in gross proceeds of approximately $27.2 million. Shares, which spiked 94% Wednesday, closed Thursday down 2% to $6.05.

-

Other major price movers (stocks priced > $1.00, volume > 50k listed on NASDAQ/NYSE):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:

ADVANCERS:

Eloxx Pharmaceuticals, Inc. (ELOX): $1.92; +21%.

Xeris Pharmaceuticals, Inc. (XERS): $3.85; +19%.

Ocuphire Pharma, Inc. (OCUP): $5.50; +13%.

Atossa Therapeutics, Inc. (ATOS): $4.44; +13%.

Strongbridge Biopharma plc (SBBP): $2.97; +13%.

DECLINERS:

Day One Biopharmaceuticals, Inc. (DAWN): $19.00; -14%.

GT Biopharma, Inc. (GTBP): $16.31; -14%.

Reneo Pharmaceuticals, Inc. (RPHM): $9.23; -14%.

SELLAS Life Sciences Group, Inc. (SLS): $10.90; -13%.

Impel NeuroPharma, Inc. (IMPL): $9.10; -13%.

Pipeline updates below:

Pipeline Database Updates

Drug Price Stage Catalyst Market Cap

AMYT – Amryt Pharma plc
FILSUVEZ (Oleogel-S10)
Epidermolysis Bullosa

$11.70
-0.12  -1%
PDUFA priority review PDUFA date under priority review November 30, 2021.
$419.8 million

ARWR – Arrowhead Pharmaceuticals Inc.
ARO-APOC3
Hypertriglyceridemia

$88.83
-0.98  -1%
Phase 2b Phase 2b trial initiation announced June 3, 2021.
$9.2 billion

AZN – AstraZeneca PLC
LYNPARZA (olaparib) - OlympiA
BRCAm adjuvant breast cancer

$57.89
-0.42  -1%
Phase 3 Phase 3 trial crossed the superiority boundary for its primary endpoint of invasive disease-free survival (iDFS) versus placebo - February 17, 2021.
$152 billion

BMY – Bristol-Myers Squibb Company
OPDIVO (nivolumab) + YERVOY (ipilimumab) - CM-648
Esophageal Cancer

$65.94
-0.89  -1%
Phase 3 Phase 3 data released April 8, 2021. Overall survival (OS) endpoint met. ASCO abstract released June 3, 2021. Overall survival 13.7 months vs. 9.1 months for chemotherapy (PD-L1 patients). Progression-free survival endpoint not met.
$147.2 billion

CHRS – Coherus BioSciences Inc.
Toripalimab
Nasopharyngeal carcinoma (NPC)

$15.07
+0.31  +2%
BLA Filing BLA rolling submission has been initiated - March 3, 2021. To be completed mid-2021.
$1.1 billion

EDSA – Edesa Biotech Inc.
EB01
Allergic contact dermatitis (ACD)

$5.29
+0.04  +1%
Phase 2b Phase 2b trial to move to second cohort of patients following positive interim analysis - June 3, 2021.
$70.1 million

HSTO – Histogen Inc.
Emricasan
COVID-19

$1.10
+0.15  +16%
Phase 1 Phase 1 top-line data released June 22, 2021 - safe and well tolerated.
$45.9 million

MRK – Merck & Company Inc. (new)
KEYTRUDA (pembrolizumab) - (KEYNOTE-564 )
Renal cell carcinoma (RCC)

$76.19
-0.56  -1%
Phase 3 Phase 3 trial met primary endpoint of disease-free survival (DFS) - April 8, 2021. Reduction in the risk of disease recurrence or death of 32% compared to placebo.
$192.9 billion

NBTX – Nanobiotix S.A.
NBTXR3 (Study 1100)
Advanced Cancers

$14.42
0.00  0%
Phase 1 Phase 1 updated data released June 3, 2021. Tumor regression was observed in 76.9% (10/13) of evaluable patients.
$496.9 million

REPL – Replimune Group Inc.
RP1 (vusolimogene oderparepvec) and LIBTAYO (cemiplimab) - CERPASS
Cutaneous squamous cell carcinoma (CSCC)

$35.23
-0.40  -1%
Phase 2 Phase 2 data due 2022.
$1.6 billion

REPL – Replimune Group Inc.
RP2 and OPDIVO (nivolumab)
Solid tumors

$35.23
-0.40  -1%
Phase 1 Phase 1 data presented June 3, 2021. 4/9 partial responses noted.
$1.6 billion

UTHR – United Therapeutics Corporation
TYVASO (treprostinil)
Idiopathic Pulmonary Fibrosis

$180.86
+0.66  +0%
Phase 3 Phase 3 trial initiation announced June 3, 2021.
$8.1 billion

VINC – Vincerx Pharma Inc.
VIP152
MYC-driven lymphomas and advanced solid tumors

$12.43
+0.67  +6%
Phase 1b Phase 1b initiation of dosing announced June 3, 2021.
$217.8 million